We have previously reported that CHC and Peg-INF-α based therapy modulate the serum concentrations of activin-A and follistatin and we have postulated that Peg-INF-α alters the serum concentrations of these proteins by regulating their production in the liver [22, 23]. The gene discussed is IFNA17; the disease is cryohydrocytosis.